TY - JOUR T1 -吸入氨曲南可改善支气管扩张患者的咳嗽和咳痰症状:< em >事后< / em > AIR-BX分析研究摩根富林明-欧洲呼吸杂志》乔和J - 10.1183/13993003.00608 -2020欧元六世- 56 - 1 SP - 2000608 AU -克莱顿,梅根·l . AU -》,迈克盟——巴克,艾伦·f . AU - Sibila Oriol盟——Goeminne Pieter AU - Shoemark,阿米莉亚AU -查尔默斯,詹姆斯d·Y1 - 2020/07/01 UR - //www.qdcxjkg.com/content/56/1/2000608.abstract N2 -介绍吸入抗生素可能改善症状评分,但目前尚不清楚治疗后哪些具体症状会得到改善。问卷数据的项目水平分析可以让我们确定哪些特定症状对治疗反应最好。方法对AIR-BX1研究和两项吸入阿曲南与安慰剂治疗支气管扩张的试验进行事后分析。从生活质量支气管扩张(QOL-B)呼吸症状量表中提取个别项目，代表9种不同症状的严重程度。使用广义线性模型来评估从基线到第一个治疗周期结束时治疗与安慰剂的症状变化，使用混合模型来评估整个16周试验的变化。结果氨曲南改善咳嗽(差异0.22,95% CI 0.08 ~ 0.37;p=0.002)，痰量(0.30,95% CI 0.15-0.44;p<0.0001)和痰液颜色(0.29,95% CI 0.15-0.43;P<0.0001)与安慰剂相比，相当于咳嗽改善20%，痰量和痰色改善25%。 Similar results were observed for cough, sputum production and sputum purulence across the trial duration (all p<0.05). Patients with higher sputum production and sputum colour scores had a greater response on the overall QOL-B (difference 4.82, 95% CI 1.12–8.53; p=0.011 for sputum production and 5.02, 95% CI 1.19–8.86; p=0.01 for sputum colour). In contrast, treating patients who had lower levels of bronchitic symptoms resulted in shorter time to next exacerbation (hazard ratio 1.83, 95% CI 1.02–3.28; p=0.042).Conclusion Baseline bronchitic symptoms predict response to inhaled aztreonam in bronchiectasis. More sensitive tools to measure bronchitic symptoms may be useful to better identify inhaled antibiotic responders and to evaluate patient response to treatment.Inhaled aztreonam improves cough and sputum production in patients with bronchiectasis but has no impact on other symptoms. More sensitive tools to measure bronchitic symptoms may be useful to enrich for responders and to evaluate patient benefit. https://bit.ly/2UMKM5i ER -